| abstract |
The present invention relates to inhibitors of nitric oxide synthase (NOS) 5 inhibitors, particularly nitric oxide synthase, which preferentially inhibit neurogenic nitric oxide synthase (nNOS) preferentially over other NOS isoforms. The NOS inhibitors of the present invention may accompany or accompany, for example, seizures, reperfusion injury, neurodegeneration, head trauma, CABG, aura, alone or in combination with other pharmaceutically active agents. Migraines, migraines with allodynia, post-central pain (CPSP), neuropathic pain, morphine / opioid-induced tolerance and It can be used to treat or prevent conditions such as hyperalgesia. |